| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > 3 Mistakes That Prevent Effective Meetings |
|
Digg It - 3 Mistakes That Prevent Effective Meetings
These mistakes ruin meetings. Here's what to do. Mistake #1: Do all of the talking. Some meetings are run According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product like a medieval court. The chairperson sits on a verbal throne while the subjects sit in respectful silence. ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in The big talker justifies this by thinking: if the other people in the meeting knew anything worthwhile, they lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. d be leading the meeting. Reality: If you’re the only one talking, you’re working too hard. In addition, re here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe alize that most people protect themselves from long monologues by sending their brains off on a holiday. Tha d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro is, no one is paying attention to the monologue. Instead, they're busy daydreaming, doodling, or dreaming. ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc The Fix: Convey large amounts of information by a memo or email. If you must deliver it verbally, call the e easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi vent a lecture instead of a meeting. And then be as brief as possible. Mistake #2) Be spontaneous. Most me nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically tings are held without an agenda or a clearly stated goal. The chairperson simply invites people to an endle and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s discussion, sort of like a party that lasts until everyone is too tired to continue. Reality: A meeting i ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi a business activity. And it should be run like a business, with a plan. If spontaneity were a universally s ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ound business strategy we would build buildings without blueprints. Of course, no smart business leader work dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod without a plan. The Fix: Set a goal for the meeting, and then support this with an agenda that accomplishe cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin that goal. Use structured activities that guide the group's efforts toward accomplishing the goal. Mistake tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen #3: Invite everyone. Some people hold meetings as if they were free. They think that since people are alre t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel dy at work, their cost is zero. Thus, they invite dozens of people to attend meetings that go on for hours ( ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust r longer). Reality: Meetings are very expensive. They use people’s time, and the payroll is often the large y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products st expense in running a business. When people hold bad meetings, they waste the most important resource in a . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de business - the work that they were hired to perform. The Fix: Plan meetings that earn a profit. Compare the elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip value of the result with the cost of the meeting, and then invite only enough people to accomplish that task tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Take Advantage of All the Benefits Your Employer Offers Do You Know That You Don't Know? (For Business Owners And Managers)
|